Claims for Patent: 6,432,656

Summary for Patent: 6,432,656

Title:	Calcilytic compounds
Abstract:	The present invention features calcilytic compounds. \"calcilytic compounds\" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
Inventor(s):	Del Mar; Eric G. (Salt Lake City, UT), Barmore; Robert M. (Salt Lake City, UT), Sheehan; Derek (Salt Lake City, UT), Van Wagenen; Bradford C. (Salt Lake City, UT), Callahan; James F. (Philadelphia, PA), Keenan; Richard M. (Malvern, PA), Kotecha; Nikesh R. (Thurmaston, GB), Lago; Maria Amparo (Audobon, PA), Southall; Linda Sue (West Chester, PA), Thompson; Mervyn (The Pinnacles, GB)
Assignee:	NPS Pharmaceuticals, Inc. (Salt Lake City, UT)
Application Number:	09/370,097
Patent Claims:	1. A method for identifying a calcilytic compound that optimally inhibits one or more calcium receptor activities in a particular cell type, the method comprising: contacting a particular type of calcium receptor-bearing cell with a calcilytic compound having the formula: ##STR87## wherein R.sub.1 is selected from the group consisting of: aryl, longer-length alk, and cyclo-alk; R.sub.2 is selected from the group consisting of: lower alk, cyclo-alk, alkoxy, H, OH, .dbd.O, C(O)OH, C(O)O-lower alk, C(O)NH-lower alk, C(O)N(lower alk).sub.2, SH, S-lower alk, NH.sub.2, NH-lower alk, and N(lower alk).sub.2 ; R.sub.3 and R.sub.4 are each independently lower alk or, together with the carbon to which they are attached, are cyclopropyl; R.sub.5 is aryl; R.sub.6 if present is either hydrogen, lower alkyl or optionally substituted lower alkenyl, wherein R.sub.6 is not present if R.sub.2 is .dbd.O; Y.sub.1 is either a covalent bond, alkylene, or alkenylene; Y.sub.2 is alkylene; Y.sub.3 is alkylene; Z is selected from the group consisting of: a covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either O, S, NH, or N-lower alk, then Y.sub.1 is not a covalent bond; further provided that Y.sub.1 and Z may together be a covalent bond, or a pharmaceutically acceptable salt or complex thereof; and determining the effect of said compound on a calcium receptor activity of said particular type of calcium receptor-bearing cell, wherein said calcilytic compound is identified by the inhibition of said calcium receptor activity. 2. The method of claim 1, wherein said method is carried out under conditions wherein influx of extracellular Ca.sup.2+ into said one or more cells is inhibited. 3. The method of claim 1, wherein said one or more cells are contacted with said compound in vitro. 4. The method of claim 1, wherein said one or more cells are contacted with said compound in vivo. 5. The method of claim 1, wherein the effect of said compound on a calcium receptor activity is determined by measuring a serum hormone level. 6. The method of claim 5, wherein said serum hormone level is selected from the group consisting of parathyroid hormone level and calcitonin level. 7. The method of claim 1, wherein the effect of said compound on a calcium receptor activity is determined by measuring a serum calcium ion concentration. 8. The method of claim 1, wherein the effect of said compound on a calcium receptor activity is determined by measuring an intracellular calcium ion concentration. 9. The method of claim 1, wherein the effect of said compound on a calcium receptor activity is determined by measuring secretion of a hormone.

Details for Patent 6,432,656

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2016-04-07